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compared to angiography-guided bifurcation PCI. Randomized data are needed to
conﬁrm the ﬁndings of this meta-analysis.
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Background: With the recent availability of randomized evidence in the era of
biocompatible drug-eluting stents (DES), we systematically reviewed the latest data
on the efﬁcacy and safety of biodegradable polymer DES versus durable polymer DES
for percutaneous coronary intervention (PCI).
Methods: MEDLINE, EMBASE and the Cochrane database were searched in May
2013 for eligible randomized controlled trials (RCTs). Primary outcomes were
mortality, myocardial infarction (MI), stent thrombosis, target lesion revascularization
(TLR) and target vessel revascularization (TVR). Secondary outcomes were late
lumen loss (LLL), minimal lumen diameter (MLD), diameter stenosis and binary
restenosis.
Results: We included 20 studies (n¼20,021). A total of 11,045 (55.2%) participants
were randomized to biodegradable polymer DES and 8,976 (44.8%) to durable
polymer DES. No signiﬁcant differences were observed in the analyses of all-cause
mortality (odds ratio (OR) 0.95, 95% conﬁdence interval (CI) 0.81 to 1.12, p¼0.54),
cardiac mortality (OR 0.95, 95% CI 0.77 to 1.17, p¼0.62), MI (OR 1.08, 95% CI 0.91
to 1.27, p¼0.37), stent thrombosis (OR 0.89, 95% CI 0.70 to 1.14, p¼0.36), TLR (OR
0.88, 95% CI 0.71 to 1.10, p¼0.26) or TVR (OR 1.05, 95% CI 0.85 to 1.29, p¼0.65).
Biodegradable polymer DES were associated with signiﬁcant improvement in most
angiographic outcomes (in-stent LLL: mean difference (MD) -0.05, 95% CI -0.09 to
-0.02, p¼0.004; in-segment LLL: MD -0.04, 95% CI -0.06 to -0.01, p¼0.004; in-stent
MLD: MD 0.08, 95% CI 0.03 to 0.14, p¼0.002; in-segment MLD: MD 0.06, 95% CI
0.02 to 0.10, p¼0.001; in-stent diameter stenosis: MD -2.27, 95% CI -4.02 to -0.52,
p¼0.01; in-segment diameter stenosis: MD -1.97, 95% CI -3.14 to -0.81, p¼0.0009)
except for binary restenosis (in-stent: OR 0.68, 95% CI 0.25 to 1.83, p¼0.44; in-
segment: OR 0.83, 95% CI 0.50 to 1.39, p¼0.49).
Conclusions: Biodegradable polymer DES signiﬁcantly improved angiographic
outcomes, with similar clinical safety and efﬁcacy proﬁles as those by durable
polymer DES. Long-term follow-up data from large-scale randomized studies are
warranted to further establish the effects of biodegradable polymer DES for PCI.
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Background: Perioperative infusion of sodium bicarbonate (NaHCO3) has been
shown to reduce the risk of contrast-induced nephropathy (CIN). However, it is
currently not known the effect NaHCO3 may have on short and long-term mortality.
The objective of this research was to conduct a meta-analysis to determine whether
NaHCO3 is associated with a reduction in mortality.
Methods: We searched MEDLINE, EMBASE, and references for published
randomized controlled trials (RCTs) comparing hydration with NaHCO3 versus
normal saline (NS) for mortality at 30-days and 1-year following coronary angiog-
raphy (index procedure). Point estimates were extracted as relative risks (RRs) and
95% conﬁdence intervals (CIs) and combined for meta-analysis using a ﬁxed-effect
model.B252 JACC Vol 62/18/Suppl B j October 27–NoResults: Eleven RCTs, including 2634 participants (NaHCO3¼1298; NS¼1303) met
eligibility criteria. Eight contributed data to summary estimates for 30-day (Fig. 1A)
and 1-year all-cause mortality (Fig. 1B). At 30-days, a total of 16 and 29 deaths
occurred in NaHCO3 and control arms, respectively (1.2% vs 2.2%; RR, 0.57; 95%
CI, 0.32-1.02; p¼0.06) compared to a total of 18 and 34 deaths at 1-year (1.4% vs
2.6%; RR, 0.54; 95% CI, 0.31-0.94; p¼0.03). There was no observed heterogeneity
for either outcome (p¼0.85 and p¼0.92), nor any evidence of reporting bias.Conclusions: Sodium bicarbonate has an important clinical impact in reducing
mortality following coronary angiography.
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Background: DES with biodegradable polymers have been developed in an attempt
to improve clinical outcomes. However, the impact of biodegradable polymers on
clinical events and ST remains controversial.
Methods: We searched Medline, the Cochrane Library and other internet sources,
without language or date restrictions for articles comparing clinical outcomes between
biodegradable polymer DES and durable polymer DES. Safety endpoints were ST
(deﬁnite, deﬁnite/probable), mortality, and myocardial infarction (MI). Efﬁcacy
endpoints were major adverse cardiac event (MACE) and target lesion revasculari-
zation (TLR).
Results: We identiﬁed 15 randomized controlled trials (n¼17,068) with a weighted
mean follow-up of 20.6 months. Compared with durable polymer DES, there was
a trend towards low incidence of deﬁnite/probable ST in biodegradable polymer DES
group, but this difference was not statistically signiﬁcant (relative risk [RR]: 0.83;
95% conﬁdence interval [CI]: 0.62-1.11; p¼0.22). Biodegradable polymer DES had
similar rates of deﬁnite ST (RR: 0.94; 95% CI: 0.66-1.33; p¼0.72), mortality (RR:
0.94; 95% CI: 0.82-1.09; p¼0.43), MI (RR: 1.08; 95% CI: 0.92-1.26; p¼0.35),
MACE (RR: 0.99; 95% CI: 0.91-1.09; p¼0.85), and TLR (RR: 0.94; 95% CI: 0.83-
1.06; p¼0.30) compared with durable polymer DES. Based on the stratiﬁed analysis
of included trials, the treatment effect on deﬁnite ST was opposite by different follow-
up times: 1 year favoring durable polymer DES, >1 year favoring biodegradable
polymer DES.
Conclusions: Biodegradable polymer DES have similar safety and efﬁcacy for
treating patients with coronary artery disease compared with durable polymer DES.
Further data with longer term follow-up are warranted to conﬁrm the potential beneﬁts
of biodegradable polymer DES.vember 1, 2013 j TCT Abstracts/POSTER/Meta-Analyses and Reviews
